SLAMF7 and plasma cell myeloma: SLAMF7 is functionally important for plasma cell survival, and its discovery prompted development of the anti-SLAMF7 antibody elotuzumab, which is FDA-approved for administration in combination with lenalidomide and dexamethasone for the treatment of R/R myeloma (86–88).